ascc3 Antibody

What is ASCC3 and what cellular functions does it perform?

ASCC3 is the largest subunit of the Activating Signal Co-integrator Complex (ASCC), functioning primarily as a 3′-5′ DNA helicase that participates in DNA repair mechanisms. It plays a critical role in maintaining genomic integrity by unwinding DNA to generate single-stranded substrates required for repair processes . ASCC3 has dual cellular localization, being present in both the cytoplasm and nucleus, which indicates its involvement in multiple cellular processes . Recent research has identified ASCC3 as an oncogenic factor that impairs host immune defense, particularly through its interactions with the STAT3 pathway in non-small cell lung cancer (NSCLC) .

What research applications are ASCC3 antibodies suitable for?

ASCC3 antibodies are validated for multiple research applications, with different products showing specific optimization profiles:

When selecting an ASCC3 antibody, researchers should consider the specific application requirements and validate the antibody in their experimental system .

How can I confirm the specificity of my ASCC3 antibody?

Confirming antibody specificity is crucial for experimental reliability. For ASCC3 antibodies, consider implementing these validation steps:

• Positive control lysates: Use cell lines known to express ASCC3, such as 293T or Daudi cells, as positive controls in Western blot applications .

• Knockdown validation: Compare antibody signal in wild-type versus ASCC3 knockdown samples to confirm specificity.

• Immunoprecipitation analysis: Perform reciprocal co-immunoprecipitation experiments to verify the antibody can recognize native ASCC3 protein complexes, similar to the validation approach used in ASCC3-ALKBH3 interaction studies .

• Multiple antibody comparison: When possible, use antibodies targeting different epitopes of ASCC3 to confirm consistent localization or expression patterns.

What are the optimal conditions for detecting ASCC3 in cancer cell lines?

When designing experiments to detect ASCC3 in cancer cell lines, consider the following methodological approach:

• Cell line selection: ASCC3 shows variable expression levels across cancer types. Prostate cancer lines (PC-3, LNCaP) and non-small cell lung cancer lines (H23) demonstrate relatively high ASCC3 expression compared to non-malignant controls .

• Protein extraction: For complete extraction of ASCC3 (251kDa), use lysis buffers containing adequate detergent concentrations and perform lysis at 4°C to preserve protein integrity.

• Western blot considerations: Use low percentage (6-8%) gels for adequate resolution of high molecular weight ASCC3, with extended transfer times (overnight at low voltage) for complete transfer.

• Immunofluorescence optimization: When performing IF staining, a permeabilization step is crucial as ASCC3 localizes to both cytoplasmic and nuclear compartments .

How should I approach ASCC3 antibody-based co-immunoprecipitation experiments?

Co-immunoprecipitation (co-IP) experiments are valuable for studying ASCC3's protein-protein interactions. Based on published methodologies:

• Antibody selection: Use antibodies validated for IP applications; polyclonal antibodies often perform better than monoclonals for co-IP.

• Lysate preparation: Prepare lysates under non-denaturing conditions to preserve protein-protein interactions.

• Cross-validation approach: Perform reciprocal co-IPs (e.g., IP with anti-ASCC3 and blot for interaction partners, then IP with partner antibody and blot for ASCC3) .

• Controls: Include IgG control IPs to identify non-specific binding.

Research has successfully employed this approach to demonstrate ASCC3 interactions with ALKBH3 in prostate cancer cell lines, confirming their functional association in DNA repair pathways .

How does ASCC3 expression pattern vary across cancer types?

ASCC3 expression shows significant variation across cancer types, with important implications for research:

This differential expression makes certain cell lines more suitable for ASCC3 functional studies, particularly those investigating its role in cancer progression .

What experimental approaches can reveal ASCC3's role in immunosuppression?

To investigate ASCC3's role in immunosuppression and tumor microenvironment modulation, consider these methodological approaches:

• Flow cytometry analysis: Assess tumor-infiltrating immune cell populations (CD8+ T cells, NK cells, dendritic cells, and regulatory T cells) in ASCC3 knockdown versus control tumors .

• Cytokine profiling: Measure changes in immunomodulatory cytokine levels in response to ASCC3 manipulation.

• STAT3 signaling assessment: Analyze phosphorylated STAT3 levels and downstream target gene expression following ASCC3 knockdown or overexpression .

• Immunotherapy response studies: Evaluate the efficacy of immune checkpoint inhibitors (anti-PD-1) in models with varying ASCC3 expression levels .

Research has demonstrated that ASCC3 overexpression promotes an immunosuppressive tumor microenvironment characterized by decreased CD8+ T cells, NK cells, and dendritic cells, while increasing regulatory T cell populations .

How can I design experiments to study ASCC3's helicase activity in DNA repair?

ASCC3's DNA helicase activity is critical for its function in DNA repair. To investigate this activity:

• Helicase activity assays: Use fluorescently labeled DNA substrates with complementary strands to assess unwinding activity in vitro.

• Site-directed mutagenesis: Generate helicase-dead ASCC3 mutants by introducing mutations in the conserved helicase domains.

• DNA damage repair kinetics: Compare DNA damage accumulation and resolution in cells expressing wild-type versus helicase-dead ASCC3 after exposure to alkylating agents like MMS (methyl methanesulfonate) .

• Single-molecule approaches: Consider advanced biophysical techniques to visualize ASCC3 helicase activity on individual DNA molecules.

Research has established that ASCC3 unwinds DNA to generate single-stranded substrates necessary for ALKBH3-mediated DNA repair, particularly in the context of alkylation damage resistance .

What methodologies are effective for studying ASCC3-ALKBH3 functional interactions?

The functional interaction between ASCC3 and ALKBH3 represents a significant area of research in DNA repair mechanisms. Effective methodologies include:

• Complex purification: Utilize affinity purification approaches with tagged ALKBH3 followed by mass spectrometry to identify interacting partners .

• Glycerol gradient sedimentation: Analyze protein complex formation through gradient fractionation followed by immunoblotting for ASCC3 and ALKBH3 .

• Functional epistasis analysis: Compare phenotypes of single versus double knockdowns of ASCC3 and ALKBH3 to assess pathway relationships.

• 3meC accumulation: Measure 3-methylcytosine accumulation using specific antibodies in genomic DNA following ASCC3 or ALKBH3 knockdown .

Research has demonstrated that in cells dependent on this pathway, loss of either ASCC3 or ALKBH3 results in increased sensitivity to alkylating agents, reduced cell proliferation, and accumulation of DNA damage markers including 3meC and pH2A.X/53BP1 foci .

How should I approach experiments investigating ASCC3's role in anti-PD-1 therapy resistance?

ASCC3's emerging role in immunotherapy resistance represents an important frontier in cancer research. To investigate this function:

• Combination therapy models: Develop in vivo models testing anti-PD-1 therapy with and without ASCC3 knockdown or inhibition .

• Tumor microenvironment analysis: Perform comprehensive immune profiling of tumors under different treatment conditions.

• STAT3 pathway inhibition studies: Compare the effects of direct STAT3 inhibition versus ASCC3 knockdown on anti-PD-1 therapy efficacy .

• Patient-derived xenograft (PDX) models: Consider using PDX models from tumors with variable ASCC3 expression to assess therapy response.

Research has shown that high ASCC3 expression impairs anti-PD-1 therapy efficacy, while ASCC3 knockdown combined with anti-PD-1 antibody treatment demonstrates synergistic efficacy in preclinical models .

What are common challenges when using ASCC3 antibodies and how can they be addressed?

Researchers may encounter several challenges when working with ASCC3 antibodies:

• High molecular weight detection issues: Due to ASCC3's large size (251kDa), Western blot detection may be challenging.

  • Solution: Use low percentage gels (6-8%), extend transfer time, and consider wet transfer methods.

• Antibody cross-reactivity concerns:

  • Solution: Validate specificity using positive controls (293T, Daudi cells) and compare multiple antibodies targeting different epitopes .

• Variable expression levels across cell types:

  • Solution: Include appropriate positive controls and optimize protein loading based on expected expression levels .

• Nuclear and cytoplasmic dual localization complicating IF interpretation:

  • Solution: Use nuclear and cytoplasmic markers for co-localization studies to clearly distinguish compartment-specific functions .

How can I interpret conflicting ASCC3 expression data across different experimental platforms?

When faced with conflicting ASCC3 expression data:

• Consider technique sensitivity differences: RNA-based methods (qPCR, RNA-seq) might not align with protein detection methods due to post-transcriptional regulation.

• Antibody epitope location: Different antibodies may recognize distinct protein domains or isoforms, potentially giving different results.

• Cell state variability: ASCC3 expression may change with cell cycle, stress conditions, or culture density.

• Integrate multiple approaches: Combine RNA and protein detection methods, using absolute quantification when possible.

• Subcellular fractionation: Analyze nuclear versus cytoplasmic fractions separately, as compartment-specific changes might be masked in whole-cell analyses.